Radiation-induced Xerostomia: Pathophysiology, Prevention and Treatment

Clinical Oncology

Volumn 21, Issue 10, 2009, Pages 737-744

  Bhide, S A ^a   Miah, A B ^a   Harrington, K J ^a   Newbold, K L ^a   Nutting, C M ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Head and neck cancer; radiation; xerostomia

Indexed keywords

AMIFOSTINE; CEVIMELINE; PERTECHNETIC ACID TC 99M; PILOCARPINE; PLACEBO; SALIVA SUBSTITUTE; VIRUS VECTOR;

ACUPUNCTURE; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVOR; CERVICAL LYMPH NODE; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; DRUG HYPERSENSITIVITY; DYSPHAGIA; GLANDOPEXY; HEAD AND NECK CANCER; HEART DISEASE; HUMAN; HYPOPHARYNX CANCER; HYPOTENSION; INTENSITY MODULATED RADIATION THERAPY; MUCOSA INFLAMMATION; NASOPHARYNX CANCER; NAUSEA; OROPHARYNX CANCER; PAROTID GLAND; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE DISTRIBUTION; RADIATION INJURY; RADIATION PROTECTION; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT DISEASE; SALIVARY GLAND SCINTISCANNING; SALIVATION DISORDER; SIALOGRAPHY; SIDE EFFECT; SJOEGREN SYNDROME; STEVENS JOHNSON SYNDROME; SURGICAL TECHNIQUE; SWEATING; TOXIC EPIDERMAL NECROLYSIS; VIRAL GENE THERAPY; VOMITING; XEROSTOMIA;

HUMANS; RADIATION INJURIES; RADIOTHERAPY; XEROSTOMIA;

EID: 70350746058     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2009.09.002     Document Type: Article

References (64)

1. Abendstein H., Nordgren M., Boysen M., et al. Quality of life and head and neck cancer: a 5 year prospective study. Laryngoscope 115 12 (2005) 2183-2192
2. Bjordal K., Ahlner-Elmqvist M., Hammerlid E., et al. A prospective study of quality of life in head and neck cancer patients. Part II: longitudinal data. Laryngoscope 111 8 (2001) 1440-1452
3. de Graeff A., de Leeuw J.R., Ros W.J., Hordijk G.J., Blijham G.H., and Winnubst J.A. A prospective study on quality of life of patients with cancer of the oral cavity or oropharynx treated with surgery with or without radiotherapy. Oral Oncol 35 1 (1999) 27-32
4. Hammerlid E., Silander E., Hornestam L., and Sullivan M. Health-related quality of life three years after diagnosis of head and neck cancer - a longitudinal study. Head Neck 23 2 (2001) 113-125
5. Hammerlid E., and Taft C. Health-related quality of life in long-term head and neck cancer survivors: a comparison with general population norms. Br J Cancer 84 2 (2001) 149-156
6. Wijers O.B., Levendag P.C., Braaksma M.M., Boonzaaijer M., Visch L.L., and Schmitz P.I. Patients with head and neck cancer cured by radiation therapy: a survey of the dry mouth syndrome in long-term survivors. Head Neck 24 8 (2002) 737-747
7. Humphrey S.P., and Williamson R.T. A review of saliva: normal composition, flow, and function. J Prosthet Dent 85 2 (2001) 162-169
8. Konings A.W., Coppes R.P., and Vissink A. On the mechanism of salivary gland radiosensitivity. Int J Radiat Oncol Biol Phys 62 4 (2005) 1187-1194
9. Chao K.S., Deasy J.O., Markman J., et al. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. Int J Radiat Oncol Biol Phys 49 4 (2001) 907-916
10. Leslie M.D., and Dische S. The early changes in salivary gland function during and after radiotherapy given for head and neck cancer. Radiother Oncol 30 1 (1994) 26-32
11. Zeilstra L.J., Vissink A., Konings A.W., and Coppes R.P. Radiation induced cell loss in rat submandibular gland and its relation to gland function. Int J Radiat Biol 76 3 (2000) 419-429
12. Leslie M.D., and Dische S. Changes in serum and salivary amylase during radiotherapy for head and neck cancer: a comparison of conventionally fractionated radiotherapy with CHART. Radiother Oncol 24 1 (1992) 27-31
13. Eisbruch A., Ten Haken R.K., Kim H.M., Marsh L.H., and Ship J.A. Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys 45 3 (1999) 577-587
14. Kosuda S., Satoh M., Yamamoto F., Uematsu M., and Kusano S. Assessment of salivary gland dysfunction following chemoradiotherapy using quantitative salivary gland scintigraphy. Int J Radiat Oncol Biol Phys 45 2 (1999) 379-384
15. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 6 (2006) 567-578
16. Bjordal K., and Kaasa S. Psychometric validation of the EORTC Core Quality of Life Questionnaire, 30-item version and a diagnosis-specific module for head and neck cancer patients. Acta Oncol 31 3 (1992) 311-321
17. Eisbruch A., Kim H.M., Terrell J.E., Marsh L.H., Dawson L.A., and Ship J.A. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 50 3 (2001) 695-704
18. Weymuller Jr. E.A., Alsarraf R., Yueh B., Deleyiannis F.W., and Coltrera M.D. Analysis of the performance characteristics of the University of Washington Quality of Life instrument and its modification (UW-QOL-R). Arch Otolaryngol Head Neck Surg 127 5 (2001) 489-493
19. Meirovitz A., Murdoch-Kinch C.A., Schipper M., Pan C., and Eisbruch A. Grading xerostomia by physicians or by patients after intensity-modulated radiotherapy of head-and-neck cancer. Int J Radiat Oncol Biol Phys 66 2 (2006) 445-453
20. Ship J.A., Eisbruch A., D'Hondt E., and Jones R.E. Parotid sparing study in head and neck cancer patients receiving bilateral radiation therapy: one-year results. J Dent Res 76 3 (1997) 807-813
21. D'Hondt E., Eisbruch A., and Ship J.A. The influence of pre-radiation salivary flow rates and radiation dose on parotid salivary gland dysfunction in patients receiving radiotherapy for head and neck cancers. Spec Care Dentist 18 3 (1998) 102-108
22. van Acker F., Flamen P., Lambin P., et al. The utility of SPECT in determining the relationship between radiation dose and salivary gland dysfunction after radiotherapy. Nucl Med Commun 22 2 (2001) 225-231
23. Valdes Olmos R.A., Keus R.B., Takes R.P., et al. Scintigraphic assessment of salivary function and excretion response in radiation-induced injury of the major salivary glands. Cancer 73 12 (1994) 2886-2893
24. Dirix P., De Keyzer F., Vandecaveye V., Stroobants S., Hermans R., and Nuyts S. Diffusion-weighted magnetic resonance imaging to evaluate major salivary gland function before and after radiotherapy. Int J Radiat Oncol Biol Phys 71 5 (2008) 1365-1371
25. Epstein J.B., Emerton S., Kolbinson D.A., et al. Quality of life and oral function following radiotherapy for head and neck cancer. Head Neck 21 1 (1999) 1-11
26. Brizel D.M., Wasserman T.H., Henke M., et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18 19 (2000) 3339-3345
27. Andreassen C.N., Grau C., and Lindegaard J.C. Chemical radioprotection: a critical review of amifostine as a cytoprotector in radiotherapy. Semin Radiat Oncol 13 1 (2003) 62-72
28. Rades D., Fehlauer F., Bajrovic A., Mahlmann B., Richter E., and Alberti W. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients. Radiother Oncol 70 3 (2004) 261-264
29. Astudillo L., Maachi B., Benyoucef A., Game X., Rives M., and Bachaud J.M. Stevens-Johnson syndrome after amifostine during radiotherapy. Int J Dermatol 43 4 (2004) 284-285
30. Lale Atahan I., Ozyar E., Sahin S., Yildiz F., Yalcin B., and Karaduman A. Two cases of Stevens-Johnson syndrome: toxic epidermal necrolysis possibly induced by amifostine during radiotherapy. Br J Dermatol 143 5 (2000) 1072-1073
31. Valeyrie-Allanore L., Poulalhon N., Fagot J.P., et al. Stevens-Johnson syndrome and toxic epidermal necrolysis induced by amifostine during head and neck radiotherapy. Radiother Oncol 87 2 (2008) 300-303
32. Buentzel J., Micke O., Adamietz I.A., Monnier A., Glatzel M., and de Vries A. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study. Int J Radiat Oncol Biol Phys 64 3 (2006) 684-691
33. Peters K., Mucke R., Hamann D., Ziegler P.G., and Fietkau R. Supportive use of amifostine in patients with head and neck tumors undergoing radio-chemotherapy. Is it possible to limit the duration of the application of amifostine?. Strahlenther Onkol 175 Suppl. 4 (1999) 23-26
34. Bennett C.L., Lane D., Stinson T., Glatzel M., and Buntzel J. Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer Invest 19 2 (2001) 107-113
35. Buntzel J., Kuttner K., Frohlich D., and Glatzel M. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Ann Oncol 9 5 (1998) 505-509
36. Hensley M.L., Hagerty K.L., Kewalramani T., et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 27 1 (2009) 127-145
37. Johnson J.T., Ferretti G.A., Nethery W.J., et al. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med 329 6 (1993) 390-395
38. LeVeque F.G., Montgomery M., Potter D., et al. A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. J Clin Oncol 11 6 (1993) 1124-1131
39. Rieke J.W., Hafermann M.D., Johnson J.T., et al. Oral pilocarpine for radiation-induced xerostomia: integrated efficacy and safety results from two prospective randomized clinical trials. Int J Radiat Oncol Biol Phys 31 3 (1995) 661-669
40. Fisher J., Scott C., Scarantino C.W., et al. Phase III quality-of-life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head-and-neck cancer - RTOG 97-09. Int J Radiat Oncol Biol Phys 56 3 (2003) 832-836
41. Warde P., O'Sullivan B., Aslanidis J., et al. A phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 54 1 (2002) 9-13
42. Eisbruch A., Ship J.A., Martel M.K., et al. Parotid gland sparing in patients undergoing bilateral head and neck irradiation: techniques and early results. Int J Radiat Oncol Biol Phys 36 2 (1996) 469-480
43. Eisbruch A., Marsh L.H., Martel M.K., et al. Comprehensive irradiation of head and neck cancer using conformal multisegmental fields: assessment of target coverage and noninvolved tissue sparing. Int J Radiat Oncol Biol Phys 41 3 (1998) 559-568
44. Blanco A.I., Chao K.S., El Naqa I., et al. Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy. Int J Radiat Oncol Biol Phys 62 4 (2005) 1055-1069
45. Bussels B., Maes A., Flamen P., et al. Dose-response relationships within the parotid gland after radiotherapy for head and neck cancer. Radiother Oncol 73 3 (2004) 297-306
46. Chao K.S., Ozyigit G., Tran B.N., Cengiz M., Dempsey J.F., and Low D.A. Patterns of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys 55 2 (2003) 312-321
47. Bhide S., Guerrero Urbano M.T., Clark C., et al. Results of intensity modulated radiotherapy (IMRT) in laryngeal and hypopharyngeal cancer: a dose escalation study. Radiother Oncol 82 (2007) S74-S75
48. Eisbruch A., Marsh L.H., Dawson L.A., et al. Recurrences near base of skull after IMRT for head-and-neck cancer: implications for target delineation in high neck and for parotid gland sparing. Int J Radiat Oncol Biol Phys 59 1 (2004) 28-42
49. Lee N., Xia P., Fischbein N.J., Akazawa P., Akazawa C., and Quivey J.M. Intensity-modulated radiation therapy for head-and-neck cancer: the UCSF experience focusing on target volume delineation. Int J Radiat Oncol Biol Phys 57 1 (2003) 49-60
50. Sultanem K., Shu H.K., Xia P., et al. Three-dimensional intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys 48 3 (2000) 711-722
51. Yao M., Dornfeld K.J., Buatti J.M., et al. Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma - the University of Iowa experience. Int J Radiat Oncol Biol Phys 63 2 (2005) 410-421
52. Nutting C., A'Hern R., Rogers M.S., et al. First results of a phase III multicenter randomized controlled trial of intensity modulated (IMRT) versus conventional radiotherapy (RT) in head and neck cancer (PARSPORT: ISRCTN48243537; CRUK/03/005). J Clin Oncol 27 18s (2009) [Abstract LBA6006]
53. Kam M.K., Leung S.F., Zee B., et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 25 31 (2007) 4873-4879
54. Pow E.H., Kwong D.L., McMillan A.S., et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 66 4 (2006) 981-991
55. Miah A.B., Bhide S.A., Guerrero-Urbano M.T., et al. Bilateral superficial lobe parotid sparing IMRT: treating base of tongue tumours: similar outcomes to unilateral whole parotid gland sparing. Radiother Oncol 90 Suppl 2 (2009) S11
56. Saarilahti K., Kouri M., Collan J., et al. Sparing of the submandibular glands by intensity modulated radiotherapy in the treatment of head and neck cancer. Radiother Oncol 78 3 (2006) 270-275
57. Jha N., Seikaly H., McGaw T., and Coulter L. Submandibular salivary gland transfer prevents radiation-induced xerostomia. Int J Radiat Oncol Biol Phys 46 1 (2000) 7-11
58. Jha N., Seikaly H., Harris J., et al. Prevention of radiation induced xerostomia by surgical transfer of submandibular salivary gland into the submental space. Radiother Oncol 66 3 (2003) 283-289
59. Epstein J.B., and Stevenson-Moore P. A clinical comparative trial of saliva substitutes in radiation-induced salivary gland hypofunction. Spec Care Dentist 12 1 (1992) 21-23
60. Fox R.I. Use of cevimeline, a muscarinic M1 and M3 agonist, in the treatment of Sjogren's syndrome. Adv Exp Med Biol 506 Pt B (2002) 1107-1116
61. Blom M., Dawidson I., Fernberg J.O., Johnson G., and Angmar-Mansson B. Acupuncture treatment of patients with radiation-induced xerostomia. Eur J Cancer B Oral Oncol 32B 3 (1996) 182-190
62. Blom M., and Lundeberg T. Long-term follow-up of patients treated with acupuncture for xerostomia and the influence of additional treatment. Oral Dis 6 1 (2000) 15-24
63. Wong R.K., Jones G.W., Sagar S.M., Babjak A.F., and Whelan T. A phase I-II study in the use of acupuncture-like transcutaneous nerve stimulation in the treatment of radiation-induced xerostomia in head-and-neck cancer patients treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 57 2 (2003) 472-480
64. Vitolo J.M., and Baum B.J. The use of gene transfer for the protection and repair of salivary glands. Oral Dis 8 4 (2002) 183-191